Sanofi Vows Appeal After Drug Injunction Stay Is Denied
Sanofi and its Regeneron Pharmaceuticals on Monday lost a bid to stay a permanent injunction of cholesterol-lowering drug Praluent ordered by a Delaware federal judge in a patent infringement suit brought...To view the full article, register now.
Already a subscriber? Click here to view full article